Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: stockdoc77 who wrote (63124)	6/5/2025 10:13:27 AM
From: erickerickson	1 Recommendation Recommended By jhcimmu Read Replies (1) \| Respond to of 63285

re: SRPT undervalued Right, but every damn time there's a buying opportunity, I have to sell something else to buy it. Decisions, decisions, decisions. Yeah, yeah, yeah. I know. I could keep some cash reserves for opportunities. At some point I'd use it and be in the exact same position I am in now. Life is so tough ;)

To: stockdoc77 who wrote (63124)	6/9/2025 4:05:39 PM
From: luckydog88	2 Recommendations Recommended By erippetoe jhcimmu Read Replies (1) \| Respond to of 63285

came across this today: 03:01 PM EDT, 06/09/2025 (MT Newswires) -- Sarepta Therapeutics (SRPT) could meet its revised outlook following a recent cut in its revenue guidance for Elevidys, Oppenheimer said in a Sunday report. Sarepta cut its Elevidys sales guidance by $550 million at the midpoint in response to heightened caution from patients and caregivers following a patient death, according to the note. Given the totality of safety and efficacy data, the report said investors are less concerned with the potential for another patient death, seeing recent case as idiosyncratic. Elevidys being taken off the market is unlikely following supportive comments on cell and gene therapies at the FDA roundtable, the report added. "We remain confident in management's ability to hit guidance and continue to see shares trading at unique levels we might not see again once overhangs are removed this year," the note said. Oppenheimer reiterated its outperform rating on the stock and its price target of $123 per share.